Global Breast Biopsy Market 2017-2021
出 版 商：Technavio
出版日期：2017/03/10
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,500 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,500 (Multi-User License)
USD 5,000 (Global-User License)
About Breast Biopsy
A breast biopsy is a procedure that involves the removal of tissue or fluid from the targeted area. The tissue is examined under a microscope and then tested to determine the presence of breast cancer. A biopsy is the only diagnostic procedure to confirm cancer. About 80% of women who undergo breast biopsy do not have breast cancer.
Technavio’s analysts forecast the global breast biopsy market to grow at a CAGR of 10.70% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global breast biopsy market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of breast biopsy devices.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Breast Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BD
‧ C.R. Bard
‧ Hologic
‧ Leica Biosystems
Other prominent vendors
‧ Argon Medical Devices
‧ Aurora Imaging
‧ Biopsybell
‧ Bracco Imaging
‧ Carestream Health
‧ Cook Medical
‧ Fischer Medical Technologies
‧ Imaging Equipment
‧ Intact Medical (a subsidiary of Medtronic)
‧ Internazionale Medico Scientifica
‧ Metaltronica
‧ NuVue Therapeutics
‧ PerkinElmer
‧ Planmed OY
‧ Sectra
‧ STERYLAB
‧ Terason
‧ ZAMAR CARE
Market driver
‧ Growing incidence of breast cancer
‧ For a full, detailed list, view our report
Market challenge
‧ Complications and risks associated with breast biopsies
‧ For a full, detailed list, view our report
Market trend
‧ Increase in reimbursement for breast biopsy
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
A breast biopsy is a procedure that involves the removal of tissue or fluid from the targeted area. The tissue is examined under a microscope and then tested to determine the presence of breast cancer. A biopsy is the only diagnostic procedure to confirm cancer. About 80% of women who undergo breast biopsy do not have breast cancer.
Technavio’s analysts forecast the global breast biopsy market to grow at a CAGR of 10.70% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global breast biopsy market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of breast biopsy devices.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Breast Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BD
‧ C.R. Bard
‧ Hologic
‧ Leica Biosystems
Other prominent vendors
‧ Argon Medical Devices
‧ Aurora Imaging
‧ Biopsybell
‧ Bracco Imaging
‧ Carestream Health
‧ Cook Medical
‧ Fischer Medical Technologies
‧ Imaging Equipment
‧ Intact Medical (a subsidiary of Medtronic)
‧ Internazionale Medico Scientifica
‧ Metaltronica
‧ NuVue Therapeutics
‧ PerkinElmer
‧ Planmed OY
‧ Sectra
‧ STERYLAB
‧ Terason
‧ ZAMAR CARE
Market driver
‧ Growing incidence of breast cancer
‧ For a full, detailed list, view our report
Market challenge
‧ Complications and risks associated with breast biopsies
‧ For a full, detailed list, view our report
Market trend
‧ Increase in reimbursement for breast biopsy
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
‧ Top-vendor offerings
PART 05: Breast cancer: An overview
‧ Background
‧ Breast cancer
‧ Breast biopsy
PART 06: Market landscape
‧ Market overview
‧ Market size and forecast
‧ Five forces analysis
PART 07: Market segmentation by product type
‧ Market overview
‧ Global breast biopsy imaging guidance systems market
‧ Global breast biopsy needles market
‧ Global breast biopsy needle-based systems market
‧ Others
PART 08: Market segmentation by modality
‧ Global breast biopsy market by modality
PART 09: Market segmentation by end-user
‧ Hospitals
‧ ASCs
‧ Research centers
‧ Others
PART 10: Geographical segmentation
‧ Breast biopsy market in Americas
‧ Breast biopsy market in EMEA
‧ Breast biopsy market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
‧ Market drivers
‧ Impact of drivers on key customer segments
‧ Market challenges
‧ Impact of challenges on key customer segments
PART 13: Market trends
‧ Increase in reimbursement for breast biopsy
‧ Growing demand for MRI and ultrasound-guided breast biopsy procedures
‧ Emergence of breast liquid biopsy tests
PART 14: Vendor landscape
‧ Competitive landscape
PART 15: Key vendor analysis
‧ BD
‧ C.R. Bard
‧ Hologic
‧ Leica Biosystems
‧ Other prominent vendors
PART 16: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Percentage of cancer types worldwide 2012
Exhibit 03: Breast cancer stages by tumor size and extent of metastasis
Exhibit 04: Snapshot of global breast biopsy market
Exhibit 05: Global breast biopsy market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Global breast biopsy market by product type
Exhibit 08: Most common biopsies for breast cancer
Exhibit 09: Global breast biopsy market by product type 2016-2021
Exhibit 10: Global breast biopsy market by product analysis 2016
Exhibit 11: Global breast biopsy market growth lifecycle analysis 2016
Exhibit 12: Global breast biopsy market by product 2016-2021 ($ millions)
Exhibit 13: Global breast biopsy market by product 2016-2021 (%)
Exhibit 14: Global breast biopsy imaging guidance systems market 2016-2021 ($ millions)
Exhibit 15: Benefits of advanced biopsy needles
Exhibit 16: Global breast biopsy needles market 2016-2021 ($ millions)
Exhibit 17: Global needle-based breast biopsy systems market 2016-2021 ($ millions)
Exhibit 18: Global other breast biopsy devices market 2016-2021 ($ millions)
Exhibit 19: Global breast biopsy market by modality
Exhibit 20: Global breast biopsy market by modality 2016 (%)
Exhibit 21: Global breast biopsy market by end-user 2016
Exhibit 22: Global breast biopsy market by geography 2016-2021
Exhibit 23: Global breast biopsy market analysis by geography 2016
Exhibit 24: Geographical presence of global breast biopsy market
Exhibit 25: Geographical overview of global breast biopsy market 2016-2021
Exhibit 26: Breast biopsy market in Americas 2016-2021 ($ millions)
Exhibit 27: Estimated number of new cancer cases and deaths in US 2016 (1000s)
Exhibit 28: Top four EMEA countries population over 65 years of age 2015 (%)
Exhibit 29: Breast biopsy market in EMEA 2016-2021 ($ millions)
Exhibit 30: Breast biopsy market in APAC 2016-2021 ($ millions)
Exhibit 31: Global breast biopsy market by geography 2016-2021 ($ millions)
Exhibit 32: Global breast biopsy market by geography 2016-2021 (%)
Exhibit 33: Government initiatives for cancer and liquid biopsy testing in some countries
Exhibit 34: Impact of drivers
Exhibit 35: Cost of biopsies for uninsured people in US 2015
Exhibit 36: Impact of challenges
Exhibit 37: Breast biopsy facility payment in US
Exhibit 38: Competitive structure of global breast biopsy market
Exhibit 39: Competitive parameters in global breast biopsy market
Exhibit 40: Market penetration of breast biopsy market vendors 2016
Exhibit 41: Global breast biopsy market share analysis 2016
Exhibit 42: Key highlights of BD
Exhibit 43: BD: Strength assessment
Exhibit 44: BD: Strategy assessment
Exhibit 45: BD: Opportunity assessment
Exhibit 46: C.R. Bard: Strength assessment
Exhibit 47: C.R. Bard: Strategy assessment
Exhibit 48: C.R. Bard: Opportunity assessment
Exhibit 49: Key highlights of Hologic
Exhibit 50: Hologic: Strength assessment
Exhibit 51: Hologic: Strategy assessment
Exhibit 52: Hologic: Opportunity assessment
Exhibit 53: Key highlights of Leica Biosystems
Exhibit 54: Leica Biosystems: Strength assessment
Exhibit 55: Leica Biosystems: Strategy assessment
Exhibit 56: Leica Biosystems: Opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
‧ Top-vendor offerings
PART 05: Breast cancer: An overview
‧ Background
‧ Breast cancer
‧ Breast biopsy
PART 06: Market landscape
‧ Market overview
‧ Market size and forecast
‧ Five forces analysis
PART 07: Market segmentation by product type
‧ Market overview
‧ Global breast biopsy imaging guidance systems market
‧ Global breast biopsy needles market
‧ Global breast biopsy needle-based systems market
‧ Others
PART 08: Market segmentation by modality
‧ Global breast biopsy market by modality
PART 09: Market segmentation by end-user
‧ Hospitals
‧ ASCs
‧ Research centers
‧ Others
PART 10: Geographical segmentation
‧ Breast biopsy market in Americas
‧ Breast biopsy market in EMEA
‧ Breast biopsy market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
‧ Market drivers
‧ Impact of drivers on key customer segments
‧ Market challenges
‧ Impact of challenges on key customer segments
PART 13: Market trends
‧ Increase in reimbursement for breast biopsy
‧ Growing demand for MRI and ultrasound-guided breast biopsy procedures
‧ Emergence of breast liquid biopsy tests
PART 14: Vendor landscape
‧ Competitive landscape
PART 15: Key vendor analysis
‧ BD
‧ C.R. Bard
‧ Hologic
‧ Leica Biosystems
‧ Other prominent vendors
PART 16: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Percentage of cancer types worldwide 2012
Exhibit 03: Breast cancer stages by tumor size and extent of metastasis
Exhibit 04: Snapshot of global breast biopsy market
Exhibit 05: Global breast biopsy market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Global breast biopsy market by product type
Exhibit 08: Most common biopsies for breast cancer
Exhibit 09: Global breast biopsy market by product type 2016-2021
Exhibit 10: Global breast biopsy market by product analysis 2016
Exhibit 11: Global breast biopsy market growth lifecycle analysis 2016
Exhibit 12: Global breast biopsy market by product 2016-2021 ($ millions)
Exhibit 13: Global breast biopsy market by product 2016-2021 (%)
Exhibit 14: Global breast biopsy imaging guidance systems market 2016-2021 ($ millions)
Exhibit 15: Benefits of advanced biopsy needles
Exhibit 16: Global breast biopsy needles market 2016-2021 ($ millions)
Exhibit 17: Global needle-based breast biopsy systems market 2016-2021 ($ millions)
Exhibit 18: Global other breast biopsy devices market 2016-2021 ($ millions)
Exhibit 19: Global breast biopsy market by modality
Exhibit 20: Global breast biopsy market by modality 2016 (%)
Exhibit 21: Global breast biopsy market by end-user 2016
Exhibit 22: Global breast biopsy market by geography 2016-2021
Exhibit 23: Global breast biopsy market analysis by geography 2016
Exhibit 24: Geographical presence of global breast biopsy market
Exhibit 25: Geographical overview of global breast biopsy market 2016-2021
Exhibit 26: Breast biopsy market in Americas 2016-2021 ($ millions)
Exhibit 27: Estimated number of new cancer cases and deaths in US 2016 (1000s)
Exhibit 28: Top four EMEA countries population over 65 years of age 2015 (%)
Exhibit 29: Breast biopsy market in EMEA 2016-2021 ($ millions)
Exhibit 30: Breast biopsy market in APAC 2016-2021 ($ millions)
Exhibit 31: Global breast biopsy market by geography 2016-2021 ($ millions)
Exhibit 32: Global breast biopsy market by geography 2016-2021 (%)
Exhibit 33: Government initiatives for cancer and liquid biopsy testing in some countries
Exhibit 34: Impact of drivers
Exhibit 35: Cost of biopsies for uninsured people in US 2015
Exhibit 36: Impact of challenges
Exhibit 37: Breast biopsy facility payment in US
Exhibit 38: Competitive structure of global breast biopsy market
Exhibit 39: Competitive parameters in global breast biopsy market
Exhibit 40: Market penetration of breast biopsy market vendors 2016
Exhibit 41: Global breast biopsy market share analysis 2016
Exhibit 42: Key highlights of BD
Exhibit 43: BD: Strength assessment
Exhibit 44: BD: Strategy assessment
Exhibit 45: BD: Opportunity assessment
Exhibit 46: C.R. Bard: Strength assessment
Exhibit 47: C.R. Bard: Strategy assessment
Exhibit 48: C.R. Bard: Opportunity assessment
Exhibit 49: Key highlights of Hologic
Exhibit 50: Hologic: Strength assessment
Exhibit 51: Hologic: Strategy assessment
Exhibit 52: Hologic: Opportunity assessment
Exhibit 53: Key highlights of Leica Biosystems
Exhibit 54: Leica Biosystems: Strength assessment
Exhibit 55: Leica Biosystems: Strategy assessment
Exhibit 56: Leica Biosystems: Opportunity assessment
